Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs. The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. The clinical development pipeline is focused on oncology and fibrosis indications. Through the internal research and collaborations with prominent labs at NIH, Johns Hopkins, Duke, University of Maryland and Penn State, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and unique PNP delivery system. The management team collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery.

Unanet provides The One Software for Projects, People & Financials (On-Premise or Cloud) that enables over 1,000 project-driven organizations to reduce costs, improve employee productivity, and provide visibility into work performed and scheduled via: Resource Planning & Skills Management Budgeting & Forecasting Time Tracking & Expense Reporting Billing & Revenue Recognition Real-Time Reporting on Project Status, Performance, Costs, etc. Integrated Financials with AR, AP, GL and Cost Pool Calculations. Introductory videos are available at: http://www.unanet.com/content/video-demonstrations #Unanet